Journal of Clinical Medicine· 2026Q2
Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort
- 0citations
- Q2SCImago
- 2026year
Short summary
Salvage autologous stem cell transplantation (ASCT) in relapsed/refractory multiple myeloma (R/R MM) achieved a 80.7% response rate by day +100 and offered a median progression-free survival of 34 months and overall survival of 67.2 months in a real-world cohort.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine